In a Q&A with The Center for Biosimilars, IP litigation associate Alexandra Valenti helps unravel the recent discussions in the Senate Judiciary Committee about ongoing attempts at patent reform.
Read the Q&A here.
Related Content
- InsightJuly 30, 2024
The Chevron Doctrine Is Dead. What Are the Implications for Business?
- AlertFebruary 13, 2024
USPTO Issues New Guidance on Patenting AI-Assisted Inventions
- AlertAugust 18, 2022
The USPTO’s Increasing Focus on FDA Submissions and the Duty of Disclosure
- AlertJuly 28, 2022
Chief Judge of Western District of Texas Changes Waco Patent Case Assignment System
- AlertJuly 7, 2022
Fintiv 2.0: USPTO Director Issues Guidance Softening Risk of Discretionary Denial
- AlertApril 27, 2022
Federal Circuit Clarifies Standard for Fair and Reasonable Exercise of Jurisdiction Based on Demand Letters
- VideoJanuary 14, 2021
Aren’t You Glad 2020 Is Over? A Look Back (and Ahead)
- AlertNovember 6, 2020
Federal Circuit Narrows Venue for Patent Infringement Suits Under the Hatch-Waxman Act
- Speaking EngagementsOctober 8, 2024 | 1:15 PM - 2:30 PM ET
ACI's 4th Annual Passport to Proficiency on the Essentials of Hatch-Waxman and BPCIA
- Press ReleaseOctober 2, 2024
Goodwin Advises Curon Biopharmaceutical in Acquisition of CN201 by Merck for $700 Million Upfront Plus up to $600 Million Milestones
- Speaking EngagementsSeptember 24, 2024
Sedona Conference WG9/10 Annual Meeting 2024
- Awards and RankingsAugust 15, 2024
The Best Lawyers in America 2025 Recognizes 312 Goodwin Lawyers
- Awards and RankingsAugust 7, 2024
Benchmark Litigation Names Fourteen Goodwin Partners to 40 & Under Hot List 2024
- Speaking EngagementsJuly 23, 2024
LAIPLA's Patents On Tap
- WebinarJuly 2, 2024
Chevron Overturned: Implications of Loper Bright and Relentless for Life Sciences
- Awards and RankingsJune 13, 2024
The Legal 500 US 2024 Recognizes 44 Goodwin Practices and 186 Lawyers